Cantor Fitzgerald Reiterates a 'Buy' on Celgene (CELG); Raising PT on Increased Confidence

Article Related Articles (1) Stock Quotes (1) Comments (0)

Cantor Fitzgerald reiterates a 'Buy' on Celgene (NASDAQ: CELG) price target of $82.00 (from $76.00).

Analyst, Mara Goldstein, said, "We are raising our price target to $82 based on data from apremilast's psoriatic arthritis program. In addition to previously announced results of the PALACE 1 trial, two additional trials, PALACE 2 & 3, demonstrated statistical significance based on ACR20 scores at 16 and 24 weeks."

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Shares of Celgene closed at $74.49 yesterday, with a 52 week range of $58.53-$80.42.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
• Deutsche Bank Takes Aegerion (AEGR) Price Target from $52 to $85
• UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform

Create E-mail Alert Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cantor Fitzgerald

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?